Patients with high NADM8 scores were older and exhibited a higher frequency of specific gene mutations in the ELN adverse risk group (e.g., TP53, SF3B1, ASXL1, U2AF1), which were reported to be enriched in elderly AML patients (41–43). The gene discussed is SF3B1; the disease is acute myeloid leukemia.